CoSense ETCOc Monitor
Commercial- Indications
- Neonatal jaundice, Hemolysis detection
Company intelligence / Profile preview
Capnia has developed an innovative non-invasive diagnostic device that improves neonatal jaundice management by detecting hemolysis early through breath analysis. Their CoSense® ETCOc Monitor enables precise intervention to prevent severe complications such as Kernicterus. The company is expanding into therapeutic areas involving nasal carbon dioxide delivery targeting migraine, cluster headaches, trigeminal neuralgia, and allergic rhinitis with promising Phase II trial results expected soon[4][6].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Capnia, Inc..